StockpollyBeta
Get App
Popularity #4,008
ACIU · NASDAQ · Biotechnology

AC Immune (ACIU)

Develops protein-misfolding therapies and diagnostics for neurodegenerative diseases.

$2.73
After hours−0.01 (−0.36%)
At close$2.74(+3.20%)

In millions of USD, except per-share figures · converted from CHF at the latest rate

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue018013111210118
Gross profit018013111210118
192224262224252521181917
Research & development151818211819192116131413
4−1665−2554054
General & administrative4−1665−2554054
Other expenses050007001500
Operating income−19−4−24−269−23−24−24−20−18−181
0−13−2−230−20001
Interest income001111110000
Interest expense000000000000
Other non-operating income01−322−302000−1
Income before tax−18−6−22−287−19−23−26−19−18−182
Income tax expense000000000000
Net income from continuing operations−18−6−22−287−19−23−26−19−18−182
Net income−18−6−22−287−19−23−26−19−18−182
EPS, basic−$0.22−$0.07−$0.22−$0.28$0.07−$0.18−$0.23−$0.26−$0.19−$0.17−$0.18$0.02
EPS, diluted−$0.22−$0.07−$0.22−$0.28$0.06−$0.18−$0.23−$0.26−$0.19−$0.17−$0.18$0.02
Weighted average shares, basic848499100100101100101991019999
Weighted average shares, diluted848499100101101100101991019999
EBITDA−18−5−21−277−19−22−25−19−17−182
Depreciation & amortization111111110100
EBIT−18−6−22−287−19−23−26−19−17−182